Although existing evidence from clinical trials has demonstrated manifestation of hepatic
adverse events with the use of immune checkpoint inhibitors (ICPIs), overall risks have yet to …

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies targeting immune checkpoint
molecules. ICIs are an immunotherapy for the treatment of many advanced malignancies …

Background Overall risks of hepatotoxicity with immune checkpoint inhibitors (ICIs) have yet
to be compared in primary liver cancers to other solid tumors. Methods We reviewed data …

The application of immune checkpoint inhibitors (ICI) in advanced cancer has been a major
development in the last decade. The indications for ICIs are constantly expanding into new …

Background Hepatocellular carcinoma (HCC) is a major health problem worldwide with
increasing incidence rates. As HCC traditionally occurs in chronically inflamed livers, this …

Immune checkpoint inhibitors (ICIs) have reshaped cancer therapy. ICIs enhance T cell
activation through various mechanisms and may help reverse the exhausted phenotype of …

Background Immune checkpoint inhibitors have revolutionised the oncological landscape in
the last few years. Possible applications include the treatment of hepatocellular carcinoma …

Immune checkpoint inhibition targeted against cytotoxic T-lymphocyte–associated antigen 4
(CTLA-4) and programmed cell death protein 1 (PD-1) has shown clinically significant …

Immune checkpoint inhibitors (ICIs) improve clinical outcomes in patients suffering from
different types of cancer. Liver toxicity is one of the immune-related adverse events …

Introduction: Development of immune-related adverse events (irAEs) has been associated
with enhanced efficacy with the use of immune checkpoint inhibitors (ICIs). It remains …